Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.95, compared with -$0.83 a year earlier. Trailing-twelve-month EPS (Diluted) was -$3.55.

Context

  • EPS (Diluted) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$2.74 (+20.1%) for the fiscal year ending Dec 2026, a slowdown from the +34.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.95-11.8% QoQ
Last fiscal yearDec 2025
-$3.43+34.0% YoY
LTMMar 2026
-$3.55-11.3% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.5%+28.2%+42.6 pp
1 year+34.0%+20.1%-13.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(3.43) USD
Year-over-year change
+34.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -11.3% is the 6th highest of 9, against a peer median of +12.5%.
ARTV Competitors
EPS (Diluted) for ARTV and competitors
Company Period LTM YoY 3-year CAGR
IFRXInflaRx N.V.LTM Mar 2026-€0.61 EUR+19.6%—
STTKShattuck Labs, Inc.LTM Mar 2026-$0.63 USD+54.7%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 USD-257.1%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$1.65 USD+33.2%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$1.73 USD+44.9%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$1.74 USD+5.4%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$3.55 USD-11.3%—
DTILPrecision BioSciences, Inc.LTM Mar 2026-$4.41 USD-86.1%—
STROSutro Biopharma, Inc.LTM Mar 2026-$307.72 USD-936.1%—
Peer median (excluding ARTV) —+12.5%—

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.